Current taxane formulations and emerging cabazitaxel delivery systems

被引：0
作者：
Boyang Sun
Robert M. Straubinger
Jonathan F. Lovell
机构：
[1] State University of New York,Department of Biomedical Engineering, University at Buffalo
[2] State University of New York,Department of Chemical and Biological Engineering, University at Buffalo
[3] State University of New York,Department of Pharmaceutical Sciences, University at Buffalo
来源：
Nano Research | 2018年 / 11卷
关键词：
cabazitaxel; Jevtana; taxanes; drug delivery systems; nanocarriers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cabazitaxel is a second-generation taxane with promising anti-tumor activity and is approved for treating hormone-refractory metastatic prostate cancer previously treated with docetaxel. Although first-generation taxanes (i.e. paclitaxel and docetaxel) have sparked broad interest in a variety of drug delivery vehicles, fewer have yet been developed for cabazitaxel. This review summarizes several clinical-stage approaches for taxane formulation and recent efforts to develop novel cabazitaxel delivery systems.
引用
收藏
页码：5193 / 5218
页数：25
相关论文
共 1017 条
  • [61] Laufman L.(1999)Disposition of [G–3H]_paclitaxel and Cremophor EL in a patient with severely impaired renal function Drug Metab. Dispos. 27 1300-1305
  • [62] Sundaram S.(1998)Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study J. Natl. Cancer Inst. 90 300-306
  • [63] Urba W. J.(1980)Suspected anaphylactic reaction to Cremophor EL Br. Med. J. 280 1353-1268
  • [64] Pritchard K. I.(1990)Hypersensitivity reactions from taxol J. Clin. Oncol. 8 1263-121
  • [65] Lee K. S.(2005)Complement activation–related pseudoallergy: A new class of drug–induced acute immune toxicity Toxicology 216 106-337
  • [66] Chung H. C.(2000)Inter–relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients Anti–Cancer Drugs 11 331-141
  • [67] Im S. A.(2001)Role of formulation vehicles in taxane pharmacology Invest. New Drugs 19 125-1457
  • [68] Park Y. H.(1999)Cremophor EL–mediated alteration of paclitaxel distribution in human blood Cancer Res. 59 1454-478
  • [69] Kim C. S.(1991)Interaction of Cremophor EL with human plasma Int. J. Biochem. 23 473-404
  • [70] Kim S. B.(1994)Effects of Cremophor EL on distribution of Taxol to serum lipoproteins Br. J. Cancer 70 401-121
234567891011